ORIC Pharmaceuticals Advances Phase 3 Trial for Prostate Cancer Drug — ORIC Pharmaceuticals, Inc.

Event summary

ORIC Pharmaceuticals initiated the Himalayas-1 global Phase 3 trial for mCRPC patients previously treated with abiraterone.
Entered a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for the Himalayas-1 trial.
Cash and investments of approximately $388 million expected to fund operations into 2H 2028.
Anticipates program updates for rinzimetostat and enozertinib in 2H 2026.

The big picture

ORIC Pharmaceuticals is positioning itself as a diversified late-stage oncology player with multiple registrational trials. The initiation of the Himalayas-1 Phase 3 trial for rinzimetostat in prostate cancer marks a significant step toward potentially practice-changing therapy, while enozertinib's progress in NSCLC could further solidify its pipeline. The company's financial runway into 2H 2028 provides a buffer for these high-stakes clinical developments.

What we're watching

Trial Execution: The pace at which the Himalayas-1 trial enrolls and progresses will determine the timeline for potential regulatory approval of rinzimetostat.
Financial Runway: Whether ORIC's $388 million cash position will be sufficient to cover operating expenses until 2H 2028, especially with multiple late-stage trials ongoing.
Competitive Dynamics: How the outcomes of enozertinib trials in NSCLC will position ORIC against existing and emerging therapies targeting EGFR mutations.